December 8, 2022 by Aurigene Tech Team Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer Nature 2022,434–439
November 9, 2022 by Aurigene Tech Team PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy
November 9, 2022 by Aurigene Tech Team Small Molecule Agents Targeting PD-1 Checkpoint Pathway for Cancer Immunotherapy: Mechanisms of Action and Other Considerations for Their Advanced Development
November 15, 2022 by Aurigene Tech Team Safety, tolerability, pharmacokinetics and pharmacodynamics of AUR101, An RORγt inhibitor, in normal healthy volunteers
November 15, 2022 by Aurigene Tech Team Discovery and clinical development of the first small molecule checkpoint inhibitor for cancer therapy
November 15, 2022 by Aurigene Tech Team Phase 2 trial of CA-170, a novel oral small molecule dual inhibitor of immune checkpoints VISTA and PD-1, in patients (pts) with advanced solid tumor and Hodgkin…
November 15, 2022 by Aurigene Tech Team Phase 2 trial of CA-170, a novel oral small molecule dual inhibitor of immune checkpoints VISTA and PD-1, in patients (pts) with advanced solid tumor and Hodgkin
